Silencing invariant chain of DCs enhances Th1 response using small interfering RNA

Cell Biology International

Volumn 31, Issue 7, 2007, Pages 663-671

  Ke, Shan ^a   Chen, Xue Hua ^a   Li, Hao ^a   Li, Jian Fang ^a   Gu, Qin Long ^b   Liu, Bing Ya ^a   Zhu, Zheng Gang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antitumor immunity; Dendritic cells; Invariant chain; Small interfering RNA

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 12P70; INTERLEUKIN 4; SMALL INTERFERING RNA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; RNA DEGRADATION; RNA INTERFERENCE; RNA SEQUENCE; TH1 CELL;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 34249052624     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2006.12.004     Document Type: Article

References (63)

1. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
2. Anderson M.S., and Miller J. Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci US A 89 (1992) 2282-2286
3. Armstrong T.D., Clements V.K., Martin B.K., Ting J.P., and Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci U S A 94 (1997) 6886-6891
4. Arunachalam B., Lamb C.A., and Cresswell P. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain. Int Immunol 6 (1994) 439-451
5. Bakke O., and Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 63 (1990) 707-716
6. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
7. Benimetskaya L., Loike J.D., Khaled Z., Loike G., Silverstein S.C., Cao L., et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med 3 (1997) 414-420
8. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., and Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 (1998) 478-480
9. +T cells. Crit Rev Immunol 16 (1996) 359-379
10. Bodmer H., Viville S., Benoist C., and Mathis D. Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science 263 (1994) 1284-1286
11. Bonehill A., Heirman C., Tuyaerts S., Michiels A., Breckpot K., Brasseur F., et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172 (2004) 6649-6657
12. Chamoto K., Kosaka A., Tsuji T., Matsuzaki J., Sato T., Takeshima T., et al. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci 94 (2003) 924-928
13. +T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63 (2003) 1555-1559
14. Dissanayake S.K., Thompson J.A., Bosch J.J., Clements V.K., Chen P.W., Ksander B.R., et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 64 (2004) 1867-1874
15. +T cell-dependent tumor eradication in vivo. J Immunol 165 (2000) 5495-5501
16. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
17. Fong L., and Engleman E.G. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18 (2000) 245-273
18. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20 (2002) 621-667
19. Hammond S.M., Bernstein E., Beach D., and Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404 (2000) 293-296
20. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
21. Hill J.A., Ichim T.E., Kusznieruk K.P., Li M., Huang X., Yan X., et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 171 (2003) 691-696
22. Hwang E.S., Szabo S.J., Schwartzberg P.L., and Glimcher L.H. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 307 (2005) 430-433
23. Ichim T.E., Li M., Qian H., Popov I.A., Rycerz K., Zheng X., et al. RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant 4 (2004) 1227-1236
24. Kampgen E., Koch N., Koch F., Stoger P., Heufler C., Schuler G., et al. Class II major histocompatibility complex molecules of murine dendritic cells: synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture. Proc Natl Acad Sci U S A 88 (1991) 3014-3018
25. Lanzavecchia A., and Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 290 (2000) 92-97
26. Magram J., Connaughton S.E., Warrier R.R., Carvajal D.M., Wu C.Y., Ferrante J., et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4 (1996) 471-481
27. Maldonado R.A., Irvine D.J., Schreiber R., and Glimcher L.H. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 431 (2004) 527-532
28. Martinez J., Patkaniowska A., Urlaub H., Luhrmann R., and Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110 (2002) 563-574
29. +T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 165 (2000) 6047-6055
30. Min W.P., Gorczynski R., Huang X.Y., Kushida M., Kim P., Obataki M., et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 164 (2000) 161-167
31. Mochizuki K., Fine N.A., Fujisawa T., and Gorovsky M.A. Analysis of a piwi-related gene implicates small RNAs in genome rearrangement in tetrahymena. Cell 110 (2002) 689-699
32. Murphy K.M. T lymphocyte differentiation in the periphery. Curr Opin Immunol 10 (1998) 226-232
33. Murphy K.M., and Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol 2 (2002) 933-944
34. Murphy K.M., Ouyang W., Farrar J.D., Yang J., Ranganath S., Asnagli H., et al. Signaling and transcription in T helper development. Annu Rev Immunol 18 (2000) 451-494
35. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190 (1999) 617-627
36. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8 (1998) 275-283
37. Olsen P.H., and Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 216 (1999) 671-680
38. Pardoll D.M. Cancer vaccines. Nat Med 4 (1998) 525-531
39. +T cell responses in antitumor immunity. Curr Opin Immunol 10 (1998) 588-594
40. Paroo Z., and Corey D.R. Challenges for RNAi in vivo. Trends Biotechnol 22 (2004) 390-394
41. Peterson M., and Miller J. Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41. Nature 357 (1992) 596-598
42. Qiu G., Goodchild J., Humphreys R.E., and Xu M. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells. Cancer Immunol Immunother 48 (1999) 499-506
43. +T-helper and a T-killer cell. Nature 393 (1998) 474-478
44. Rimsza L.M., Roberts R.A., Miller T.P., Unger J.M., LeBlanc M., Braziel R.M., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103 (2004) 4251-4258
45. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
46. Senn C., Hangartner C., Moes S., Guerini D., and Hofbauer K.G. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides. Eur J Pharmacol 522 (2005) 30-37
47. Serwe M., Reuter G., Sponaas A., Koch S., and Koch N. Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation. Int Immunol 9 (1997) 983-991
48. Smith C.M., Wilson N.S., Waithman J., Villadangos J.A., Carbone F.R., Heath W.R., et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5 (2004) 1143-1148
49. Son Y.I., Egawa S., Tatsumi T., Redlinger Jr. R.E., Kalinski P., and Kanto T. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 262 (2002) 145-157
50. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
51. Stein C.A. Does antisense exist?. Nat Med 1 (1995) 1119-1121
52. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
53. Steinman R.M., and Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94 (2001) 459-473
54. Stockinger B., Pessara U., Lin R.H., Habicht J., Grez M., and Koch N. A role of Ia-associated invariant chains in antigen processing and presentation. Cell 56 (1989) 683-689
55. Toes R.E., Ossendorp F., Offringa R., and Melief C.J. CD4 T cells and their role in antitumor immune responses. J Exp Med 189 (1999) 753-756
56. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
57. Trinchieri G., and Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res Immunol 146 (1995) 423-431
58. + T cells in antitumor immunity. Trends Immunol 22 (2001) 269-276
59. Weber D.A., Evavold B.D., and Jensen P.E. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274 (1996) 618-620
60. Yang D., Lu H., and Erickson J.W. Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos. Curr Biol 10 (2000) 1191-1200
61. You Z., Hester J., Rollins L., Spagnoli G.C., van der Bruggen P., and Chen S.Y. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 61 (2001) 197-205
62. Zamore P.D., Tuschl T., Sharp P.A., and Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 (2000) 25-33
63. + T-cell responses and tumor immunity. Blood 102 (2003) 4137-4142